[HTML][HTML] Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review

MM Sampaio, MLC Santos, HS Marques… - World journal of …, 2021 - ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

[HTML][HTML] Hydroxychavicol as a potential anticancer agent

NA Mohamad, AA Rahman… - Oncology …, 2023 - spandidos-publications.com
Piper betle leaves are widely cultivated in Malaysia, India, Indonesia and Thailand. They
have been used as a traditional medicine for centuries due to their medicinal properties …

Black pepper and piperine induce anticancer effects on leukemia cell line

S Banerjee, P Katiyar, V Kumar, SS Saini… - Toxicology …, 2021 - academic.oup.com
The black pepper, most commonly used in Indian cuisines for ages, is considered as “king of
spices.” The present study evaluates the anticancer potential of black pepper and its main …

HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

H Ureshino, T Shindo, H Tanaka, H Saji… - Molecular Cancer …, 2021 - AACR
Abstract Treatment-free remission (TFR) is one of the therapeutic goals for patients with
chronic phase chronic myeloid leukemia (CML-CP). Although previous reports indicated that …

KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study

H Ureshino, Y Ueda, S Fujisawa, K Usuki… - Blood …, 2024 - ashpublications.org
Achievement of treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI)
discontinuation in patients who show a durable deep molecular response (DMR) during TKI …

[HTML][HTML] Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia

P Kwaśnik, K Giannopoulos - Journal of Personalized Medicine, 2021 - mdpi.com
Tyrosine kinases inhibitors (TKIs) revolutionized chronic myeloid leukemia (CML) treatment
for many years, prolonging patients' life expectancy to be comparable to age-matched …

Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors

S Okamoto, H Ureshino, A Kawaguchi… - International Journal of …, 2020 - Springer
BCR-ABL1 tyrosine kinase inhibitors (TKIs) have dramatically improved survival outcomes in
patients with chronic phase chronic myeloid leukemia (CML-CP) and are associated with a …

Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors

Y Hong, R Wen, G Wu, S Li, W Liu, Z Chen… - International …, 2022 - Elsevier
Background Myeloid-derived suppressor cell (MDSC)-mediated immune suppression, and
natural killer (NK) and/or T cell-mediated immune responses play important roles in Chronic …

[HTML][HTML] Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review

M Asif, M Amir, A Hussain, NM Achakzai… - Medicine, 2022 - journals.lww.com
Severe acute respiratory syndrome (SARS) caused by a novel coronavirus-2 (CoV-2), also
known as COVID-19, has spread rapidly worldwide since it is recognized as a public health …

The First Report of the Prevalence of COVID-19 in Chronic Myelogenous Leukemia Patients in the Core Epidemic Area of China: A Multicentre, Cross-Sectional …

DY Wang, JM Guo, ZZ Yang, Y You, Z Chen, SM Chen… - 2020 - papers.ssrn.com
Background: Since late December 2019, the outbreak of the novel coronavirus disease,
COVID-19, that began in Wuhan, has become endemic in China and more than 100 …